Bone marrow cell therapy in cardiovascular disease drives us slowly to a better identification of the active cell
Insights
Bone marrow mononuclear cells (BM-MNCs) show promise in regenerating tissue after acute myocardial infarction (AMI). These cells can overcome smoking-related damage, suggesting they are more than just endothelial progenitor cells.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Cell Therapy
Background:
- Acute myocardial infarction (AMI) poses significant challenges for cardiac tissue regeneration.
- Endothelial progenitor cell (EPC) and stem cell therapies are investigated for AMI recovery.
- Previous research highlighted the role of progenitors in AMI patients and their correlation with therapy efficacy.
Purpose of the Study:
- To analyze progenitor cells in the blood and bone marrow of AMI patients.
- To correlate progenitor levels with the efficacy of bone marrow mononuclear cell (BM-MNC) therapy.
- To investigate the influence of smoking status on these cellular components and therapy outcomes.
Main Methods:
- Analysis of progenitor cells in blood and bone marrow samples from AMI patients.
- Correlation of progenitor cell levels with BM-MNC therapy outcomes.
- Assessment of the impact of smoking on endothelial lineage and progenitor cell function.
Main Results:
- Bone marrow mononuclear cells (BM-MNCs) demonstrated the ability to counteract smoking-induced alterations in the endothelial lineage.
- Endothelial progenitor cells (EPCs) were found to be unlikely to be the sole active component in BM-MNC therapy for AMI.
- A complex cellular composition within BM-MNCs contributes to therapeutic efficacy in AMI.
Conclusions:
- BM-MNCs possess regenerative capabilities in AMI that extend beyond the direct action of EPCs.
- The cellular complexity of BM-MNCs is crucial for understanding their therapeutic potential in acute myocardial infarction.
- Therapeutic strategies for AMI should consider the multifaceted nature of cell therapy components.
Abstract:
Endothelial progenitor cell therapy and stem cell therapy have been proposed in regeneration of acute myocardial infarction (AMI). In the previous issue of Stem Cell Research & Therapy, Lamirault and colleagues described a strong analysis of progenitors in blood and bone marrow of patients collected after AMI, and correlated these levels to bone marrow mononuclear cell (BM-MNC) therapy efficacy and smoking status. The main results are that BM-MNCs can override smoking alteration in endothelial lineage and confirm that endothelial progenitor cells are probably not by themselves the active component of BM-MNC in AMI. This paper allows one to better appreciate the cellular complexity of cell therapy approach in AMI.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Stem Cell Culture


